Morgans Research
Morgans_Strong_growth_across_major_sales_engines
Steady for now but potential growth driver ahead – 28 April 2022
Bridging the feedback loop to CPAP – February 22 2022
Lying in wait – 28 October 2021
Buyers on weakness – 24 August 2021
Growth mode re-engaged – 23 February 2021
A strong run but more to come – 21 October 2020
Muddy result, clearer outlook – 21 August 2019
Pain for no gain – 27 November 2018
Coming into a seasonally strong period – 21 November 201
7
A transitional year – 26 April 2017
Building for growth – 18 August 2016
Moving down the supply chain – 29 May 2016
Wilsons
Wilsons Equity Research Report – SOM – 26 July 2022
Retaining guidance following a patchy 3Q22 – 27 April2022
CPAP had better watch out! – 23 February 2022
Pricing in structural innovation
– 25 August 2021
BUY: And suddenly, Germany – 22 August 2019
BUY: US sales growth equals margin and EPS – 25 July 2019
New BUY: Back to doing what they are world’s best at – 21 February 2019
HOLD: RSS pull-back a necessary mea culpa – 23 August 2018
BUY: Scrappy 1Q – Europe the powerhouse
supporting outlook and RSS investment – 1 November 2017
BUY: US channel conflicts abating in Q4- 27 April 2017
An eye on RSS channel conflict but the core
offering to prevail in US direct market – 24 February 2017
RSS taking patients in Oklahoma; good Q2 – 24 January 2017
Record Q1, SCA progress and France ratchets up reimbursement for oral appliance therapy – 19 October 2016
Organic goodness – 19 August 2016
Exciting FY17 ahead for core earnings, SCA
clinic roll-out and new management – 25 July 2016
MAS Appeal – 1 June 2016
Sustained European growth underpins a
solid Q2 – upgrading FY16 – 19 January 2016
Others
SOM Research Note Update – 9 September 2022
MST Access – SOM Update – 27 July 22
MST Access – SOM Update – 2 May 2022
MST Access – SOM Initiation – 28 February 2022
Select Equities Stock Update -11 September 2019
Select Equities Stock Update – 20 January 2016
How can we help?